Pharmaceutics 2012, 4(3), 479-493; doi:10.3390/pharmaceutics4030479
Article

Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan

1 Epidemiology, Janssen Pharmaceutical K.K., 2-5-3, Nishi-Kanda, Chiyoda-ku, Tokyo 101-0065, Japan 2 Pro-Bono Pharmacoepidemiologists Committee in Japan, Japan 3 Clinical Data and Biostatistics, Daiichi Sankyo Co. Ltd., 1-2-58, Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan 4 Sales planning group, Japan Medical Research Institute Co. Ltd. 9-1 Marunouchi 1-chome, Chiyoda-ku, Tokyo 100-6739, Japan 5 Nihon Chouzai Co. Ltd. 9-1 Marunouchi 1-chome, Chiyoda-ku, Tokyo 100-6737, Japan
* Author to whom correspondence should be addressed.
Received: 11 June 2012; in revised form: 8 August 2012 / Accepted: 30 August 2012 / Published: 19 September 2012
(This article belongs to the Special Issue Drug Safety and Pharmacovigilance)
PDF Full-text Download PDF Full-Text [240 KB, uploaded 19 September 2012 16:57 CEST]
Abstract: After the launch of dipeptidyl peptidase-4 (DPP-4), a new oral hypoglycemic drug (OHD), in December 2009, severe hypoglycemia cases were reported in Japan. Although the definite cause was unknown, co-administration with sulfonylureas (SU) was suspected as one of the potential risk factors. The Japan Association for Diabetes Education and Care (JADEC) released a recommendation in April 2010 to lower the dose of three major SUs (glimepiride, glibenclamide, and gliclazide) when adding a DPP-4 inhibitor. To evaluate the effectiveness of this risk minimization action along with labeling changes, dispensing records for 114,263 patients prescribed OHDs between December 2008 and December 2010 were identified in the Nihon-Chouzai pharmacy claims database. The adherence to the recommended dosing of SU co-prescribed with DPP-4 inhibitors increased from 46.3% before to 63.8% after the JADEC recommendation (p < 0.01 by time-series analysis), while no change was found in those for SU monotherapy and SU with other OHD co-prescriptions. The adherence was significantly worse for those receiving a glibenclamide prescription. The JADEC recommendation, along with labeling changes, appeared to have a favorable effect on the risk minimization action in Japan. In these instances, a pharmacy claims database can be a useful tool to evaluate risk minimization actions.
Keywords: Sulfonylurea; DPP-4 inhibitors; hypoglycemia; evaluation of risk minimization action; pharmacy claims; labeling change

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Kimura, T.; Shiosakai, K.; Takeda, Y.; Takahashi, S.; Kobayashi, M.; Sakaguchi, M. Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan. Pharmaceutics 2012, 4, 479-493.

AMA Style

Kimura T, Shiosakai K, Takeda Y, Takahashi S, Kobayashi M, Sakaguchi M. Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan. Pharmaceutics. 2012; 4(3):479-493.

Chicago/Turabian Style

Kimura, Tomomi; Shiosakai, Kazuhito; Takeda, Yasuaki; Takahashi, Shinji; Kobayashi, Masahiko; Sakaguchi, Motonobu. 2012. "Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan." Pharmaceutics 4, no. 3: 479-493.

Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert